Recombinant Human Glypican 3 Fc Chimera Protein, CF

When Recombinant Human FGF basic/FGF2/bFGF (233-FB) is immobilized at 0.500 µg/mL (100 µL/well), Recombinant Human Glypican 3 Fc Chimera Protein (Catalog # 11078-GP) binds with an ED50 of 0.0120-0.120 µg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Glypican 3 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human FGF basic/FGF2/bFGF (Catalog # 233-FB/CF) is immobilized at 0.500 µg/mL (100 µL/well), Recombinant Human Glypican 3 Fc Chimera Protein binds with an ED₅₀ of 0.0120-0.120 µg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Glypican 3 protein
  

  Human Glypican 3 (Gln25-His559) Accession # P51654.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P51654.1
• N-terminal Sequence: No results obtained. Gln25 inferred from enzymatic pyroglutamate treatment revealing Pro26 and Ser359.
• Structure / Form: Disulfide-linked homodimer. Glypican 3 is subject to endoproteolytic processing by proprotein convertases (PC). By amino acid sequencing, Two subunits (Alpha and Beta) are present (Alpha inferred to start with Gln25 and Beta starting with Ser359). They are associated via disulfide bonds.
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 87 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 230-330 kDa, under non-reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Glypican 3 Fc Chimera Protein, CF

• DGSX
• Glypican 3
• glypican proteoglycan 3
• glypican-3
• GPC3
• GTR2-2
• heparan sulphate proteoglycan
• Intestinal protein OCI-5
• MXR7
• OCI5
• OCI-5
• secreted glypican-3
• SGB
• SGBS
• SGBS1SDYS

Background

Glypican 3 (GPC3), also known as OCI5 and MXR7, is a member of the heparan sulfate proteoglycan (HSPG) family (1). In mammals, six glypican family members have been identified, all sharing a structurally common extracellular domain (ECD) with a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C‑terminal GPI attachment site. The ECD of GPC3 can be cleaved by furin to produce two subunits that are linked by disulfide bonds: a 40 kDa N‑terminal alpha subunit that can be secreted into the blood and a 30 kDa membrane-bound C‑terminal beta subunit containing two HS glycan chains (1-3). Within ECD, human GPC3 shares 96% amino acid sequence identity with both mouse and rat GPC3. Several isoforms of GPC3 due to alternative splicing have been reported (1). GPC3 is widely expressed on the membrane of various embryonic cells, but not on those in adult liver, and is involved in the regulation of growth and development of the body (4). GPC3 is over-expressed in hepatocellular carcinomas and binding of GPC3 to CD81 promotes development of carcinomas by activation of Hippo pathways in hepatocytes (5). GPC3 is an important biomarker present in the serum of hepatocellular carcinoma patients, which distinguishes benign from cancerous nodules (6). Loss-of-function mutations in GPC3 are associated with Simpson-Golabi-Behmel (SGB) syndrome, a condition characterized by tissue overgrowth (dysmorphogenesis) (7).

1. Ho, M. and Kim, H. (2012) Eur. J. Cancer. 47:333.
2. Haruyama, Y. and Kataoka, H. (2016) World J. Gastroenterol. 22:275.
3. Shimizu, Y. et al. (2019) Front Oncol. 9:248.
4. Gonzales, A.D. et al. (1998) J. Cell Biol. 141:1407.
5. Xue, Y. et al. (2018) Am J Pathol. 188(6):1469.
6. Ge, S. et al. (2018) Filmus, Int J Clin Exp Pathol. 11(12):5774.
7. Pilia, G. et al. (1996) Nature Genet.12:241.

Bioinformatics

• Uniprot:
  • P51654.1()